• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?

作者信息

Messerli Franz H, Bavishi Chirag, Bangalore Sripal

机构信息

Swiss Cardiovascular Center, University of Bern, Switzerland (F.H.M.).

Department of Cardiology, Lifespan Cardiovascular Institute, Warren Alpert Medical School at Brown University, Providence, RI (C.B.).

出版信息

Circulation. 2022 Feb 8;145(6):413-415. doi: 10.1161/CIRCULATIONAHA.121.057835. Epub 2022 Feb 7.

DOI:10.1161/CIRCULATIONAHA.121.057835
PMID:35130055
Abstract
摘要

相似文献

1
Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?我们为何仍在处方血管紧张素转换酶抑制剂？
Circulation. 2022 Feb 8;145(6):413-415. doi: 10.1161/CIRCULATIONAHA.121.057835. Epub 2022 Feb 7.
2
Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction.
Expert Opin Investig Drugs. 2003 Mar;12(3):501-7. doi: 10.1517/13543784.12.3.501.
3
The clinical use of angiotensin-converting enzyme inhibitors.血管紧张素转换酶抑制剂的临床应用。
Prog Cardiovasc Dis. 2004 Sep-Oct;47(2):116-30. doi: 10.1016/j.pcad.2004.04.003.
4
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction.
J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):397. doi: 10.1177/1074248419841636. Epub 2019 Apr 29.
5
Reply to Letter to the Editor-Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction.
J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):398. doi: 10.1177/1074248419845924. Epub 2019 May 1.
6
Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.血管紧张素转换酶抑制剂比血管紧张素受体阻滞剂降低死亡率：系统评价和荟萃分析。
Eur J Prev Cardiol. 2017 Dec;24(18):1914-1924. doi: 10.1177/2047487317728766. Epub 2017 Sep 1.
7
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂在心肌梗死、中风和死亡风险方面的比较：一项荟萃分析。
J Hypertens. 2008 Jul;26(7):1282-9. doi: 10.1097/HJH.0b013e328306ebe2.
8
Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.老年急性心肌梗死后应用血管紧张素转换酶抑制剂或血管紧张素Ⅱ受体阻滞剂患者发生严重不良事件的发生率和危险因素。
Pharmacotherapy. 2018 Jan;38(1):29-41. doi: 10.1002/phar.2051. Epub 2017 Dec 11.
9
Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.急性心肌梗死患者当代治疗后血管紧张素 II 受体阻滞剂与血管紧张素转换酶抑制剂的比较疗效：韩国心肌梗死工作组（KorMI）注册研究结果
Am J Cardiovasc Drugs. 2015 Dec;15(6):439-49. doi: 10.1007/s40256-015-0140-5.
10
AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.血管紧张素Ⅱ1型受体阻断用于预防心肌梗死后心血管事件
Expert Rev Cardiovasc Ther. 2004 Nov;2(6):891-902. doi: 10.1586/14779072.2.6.891.

引用本文的文献

1
General practitioners' perspectives, preferences, and practices in prescribing antihypertensive medication in primary, uncomplicated hypertension.全科医生在原发性单纯性高血压患者中开具抗高血压药物的观点、偏好及实践
Fam Pract. 2025 Aug 14;42(5). doi: 10.1093/fampra/cmaf059.
2
Impact of antihypertensive drug classes on cardiovascular outcomes: insights from the STEP study.抗高血压药物类别对心血管结局的影响：STEP研究的见解
BMC Med. 2025 Jul 1;23(1):365. doi: 10.1186/s12916-025-04158-z.
3
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study.
血管紧张素转换酶抑制剂与血管紧张素II受体阻滞剂对老年2型糖尿病患者心血管结局的比较疗效：一项目标试验模拟研究
Cardiovasc Diabetol. 2025 May 6;24(1):194. doi: 10.1186/s12933-025-02753-1.
4
Angiotensin-Converting Enzyme Inhibition as a Potential Risk Factor for Periprosthetic Joint Infection Following Total Knee Arthroplasty.血管紧张素转换酶抑制作为全膝关节置换术后假体周围关节感染的潜在危险因素
Arthroplast Today. 2025 Feb 25;32:101641. doi: 10.1016/j.artd.2025.101641. eCollection 2025 Apr.
5
Decreased risk of radiation pneumonitis with concurrent use of renin-angiotensin system inhibitors in thoracic radiation therapy of lung cancer.在肺癌胸部放射治疗中同时使用肾素-血管紧张素系统抑制剂可降低放射性肺炎的风险。
Front Med (Lausanne). 2023 Oct 12;10:1255786. doi: 10.3389/fmed.2023.1255786. eCollection 2023.
6
New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT.血管紧张素 II 受体阻滞剂与血管紧张素转换酶抑制剂为基础的抗高血压药物治疗方案的新使用者与心血管疾病事件：ACCORD-BP 和 SPRINT 的二次分析。
J Am Heart Assoc. 2023 Sep 5;12(17):e030311. doi: 10.1161/JAHA.123.030311. Epub 2023 Aug 30.
7
Chemical Synthesis, Safety and Efficacy of Antihypertensive Candidate Drug 221s (2,9).抗高血压候选药物 221s（2,9）的化学合成、安全性和功效。
Molecules. 2023 Jun 25;28(13):4975. doi: 10.3390/molecules28134975.
8
ACE-Inhibitors in Hypertension: A Historical Perspective and Current Insights.血管紧张素转换酶抑制剂在高血压中的应用：历史回顾与当前认识。
Curr Hypertens Rep. 2023 Sep;25(9):243-250. doi: 10.1007/s11906-023-01248-2. Epub 2023 Jun 7.
9
Impact of Antihypertensive Drug Class on Outcomes in SPRINT.SPRINT 研究中降压药种类对结局的影响。
Hypertension. 2022 May;79(5):1112-1121. doi: 10.1161/HYPERTENSIONAHA.121.18369. Epub 2022 Mar 9.